BDX-XL2, EarlyCDT®-Lung, Blood Test for Early Detection of Lung Cancer
EarlyCDT-Lung is a screening blood test used as an aid in risk assessment and the early detection of lung cancer in high-risk patients. High risk patients are patients exposed to lung carcinogens such as tobacco smoke and asbestos. The EarlyCDT-Lung test is a blood test based on enzyme linked immunosorbent assay (ELISA) that detects seven autoantibodies (p53, NY-ESO-1, CAGE, GBU4-5, MAGE-A4, SOX2, HuD) produced and secreted from tumor cells. It has been shown that tumor cells produce altered and abnormally expressed or mutated proteins (autoantigens) which are then recognized by the immune system as ‘non-self’ and the immune system produces antibodies against them.
Most recent publications show that such autoantibodies may arise in the early stages of lung cancer development, and can also be present at later stages. They exist in sufficient quantity and size to be measurable in blood even when the tumor may be small and/or localized. Elevated levels of autoantibodies beyond a predetermined cutoff are indicative of increased risk of lung cancer. Such a finding necessitates follow-up test(s) such as Computed Tomography (CT) in accordance with current guidelines for management of pulmonary nodules (the Fleischner guidelines). Therefore, elevation of any one of the seven autoantibodies (p53, NY-ESO-1, CAGE, GBU4-5, MAGE-A4, SOX2, HuD) above a predetermined cut-off value suggests that a cancer may be present or will develop. The key advantage of EarlyCDT-Lung is its ability to detect lung cancer earlier, and with higher sensitivity and specificity than low dose CT alone, which is the current standard diagnostic imaging test.
EarlyCDT-Lung test is used as a screening for early detection of lung cancer and risk assessment in patients at high-risk for lung cancer. In addition, EarlyCDT-Lung can be used when an individual is at increased risk, but does not meet the criteria for annual CT screening or, when individuals are unwilling or unable to undergo annual CT screening.
- Screening for early detection of lung cancer and risk assessment in high-risk patients
- To support imaging radiology tests such as Computed Tomography (CT) in accordance with current guidelines for management of pulmonary nodules (e.g., the Fleischner guidelines)
- Can be used when individual is at increased risk, but does not meet the criteria for annual CT screening or, when individuals are unwilling or unable to undergo annual CT screening
Positive or elevated levels of any one of the seven autoantibodies (p53, NY-ESO-1, CAGE, GBU4-5, MAGE-A4, SOX2, HuD) above a predetermined cut-off value suggests that a tumor may be present or will develop.
Increased in:
- Non-small cell lung cancer
- Small cell lung cancer
- Adenocarcinoma of lungs
Negative
Serum (SST).
Stability
- Ambient: 3-5 days
- Refrigerated: 7 days
- Frozen: 1 month
Lung biopsy, KRAS, EGFR, BRAF, ALK, CEA.
- Lung Cancer. 2014 Jan;83(1):51-5 [PMID: 24268382]
- Tumour Biol. 2012 Oct;33(5):1319-26. [PMID: 22492236]
- Ann Oncol. 2011 Feb;22(2):383-9. [PMID: 20675559]
- J Thorac Dis. 2013 Oct;5(5):618-25. [PMID: 24255775]
- Cancer Prev Res (Phila). 2011 Jul;4(7):1126-34. [PMID: 21733826]